Testing a new drug combo for children with returning solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 25 years old.
- Have a solid tumor that has come back or not responded to treatment.
- Not have had the exact combination of irinotecan and temozolomide together before.
- Have adequate bone marrow, kidney, and liver function (checked by blood tests).
- Be recovered from side effects of any prior treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or not responded to treatment. The goal is to see if this combination can shrink or control the tumor.
This trial tests a new combination of three chemotherapy drugs (irinotecan liposomes, temozolomide, and vincristine) for children and teens with solid tumors that have not responded to or have come back after standard treatment. The goal is to see if this combination can shrink or control the cancer.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Hear when a new Refractory Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.